Bristol-Myers Gets EU OK for Opdivo Flat Dosing in Melanoma

Bristol-Myers Squibb Co. (BMY) Thursday said the European Commission approved a flat-dosing schedule for its cancer drug Opdivo in adults with the skin cancer melanoma.
The New York biopharmaceutical company said the approval covers a dosing of 240 milligrams infused over 30 minutes every two weeks or 480 milligrams infused over 60 minutes every four weeks for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
The European Medicines Agency’s Committee for Medicinal Products for Human Use last month recommended approval of the flat-dosing schedule.

https://www.marketscreener.com/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Myers-Gets-EU-OK-for-Opdivo-Flat-Dosing-in-Melanoma-29448053/